What are the diagnostic criteria and first‑line treatment for a reproductive‑age woman with oligomenorrhea, clinical hyperandrogenism and polycystic ovarian morphology?

Polycystic Ovary Syndrome: Diagnosis and First-Line Treatment

Diagnostic Criteria

Use the Rotterdam criteria: diagnose PCOS when at least two of the following three features are present—oligomenorrhea/anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound—after excluding other causes of hyperandrogenism. 1, 2

Clinical Assessment

• Document menstrual cycle length; cycles >35 days indicate chronic anovulation, while cycles 32–35 days require ovulatory assessment 1, 3
• Examine for clinical hyperandrogenism: hirsutism (particularly facial, chest, and lower abdomen), acne resistant to standard therapy, and androgenic alopecia (vertex, crown, or bitemporal pattern) 1, 3
• Calculate BMI and waist-hip ratio; a ratio >0.9 indicates central obesity and heightened metabolic risk 1, 4
• Look for acanthosis nigricans in neck folds, axillae, and groin as a marker of insulin resistance 1

Laboratory Testing

Measure total testosterone by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the single best initial biochemical marker, with 74% sensitivity and 86% specificity; if unavailable, calculate free testosterone using the Vermeulen equation from high-quality total testosterone and SHBG measurements, which yields 89% sensitivity and 83% specificity. 5, 1, 4

• Obtain TSH to exclude thyroid disease as a cause of menstrual irregularity 1, 4
• Measure morning resting prolactin; levels >20 µg/L warrant further evaluation for hyperprolactinemia 1, 4
• If total testosterone and free testosterone are normal but clinical suspicion remains high, measure androstenedione (75% sensitivity, 71% specificity) and DHEAS (75% sensitivity, 67% specificity) 5, 4
• Do not measure insulin or C-peptide routinely; physical signs of insulin resistance are sufficient for assessment 4

Ultrasound Criteria

• Use transvaginal ultrasound with ≥8 MHz transducer frequency in adults 5, 1
• Polycystic ovarian morphology is defined by ≥20 follicles (2–9 mm diameter) per ovary, which has 87.64% sensitivity and 93.74% specificity 5, 1, 4
• Alternatively, ovarian volume >10 mL can be used when accurate follicle counting is difficult 5, 1
• Do not use ultrasound in adolescents <8 years post-menarche or <20 years of age due to poor specificity and high false-positive rates 1, 4
• Do not use anti-Müllerian hormone (AMH) for diagnosis due to lack of standardization, no validated cut-offs, and significant overlap between women with and without PCOS 1, 4

Mandatory Exclusions

• Rule out Cushing's syndrome if buffalo hump, moon facies, hypertension, abdominal striae, or easy bruising are present 1, 4
• Exclude androgen-secreting tumors if rapid onset of severe virilization, marked clitoromegaly, or very high testosterone levels (>150–200 ng/dL) occur 1, 4
• Consider non-classic congenital adrenal hyperplasia if DHEAS is elevated (>3800 ng/mL in women aged 20–29) 4
• Distinguish from functional hypothalamic amenorrhea, which presents with low LH, no hyperandrogenism, and is associated with excessive exercise, stress, or low body weight 5, 4

Metabolic Screening

Screen all women with PCOS for metabolic dysfunction regardless of BMI, because insulin resistance occurs independently of body weight. 1, 4

• Perform a 2-hour oral glucose tolerance test with 75 g glucose load to detect impaired glucose tolerance or type 2 diabetes 1, 4
• Obtain fasting lipid panel (total cholesterol, LDL, HDL, triglycerides) to assess cardiovascular risk 1, 4
• Measure blood pressure annually 1
• Check 25-hydroxy-vitamin D, as deficiency is present in 67–85% of women with PCOS 1

---

First-Line Treatment

Lifestyle Modification (All Patients)

Implement a multicomponent lifestyle program combining dietary modification, structured physical activity (aerobic and resistance exercise), and behavioral counseling as first-line therapy for all women with PCOS, regardless of BMI. 1, 4

• Weight loss of as little as 5% of initial body weight significantly improves metabolic parameters, insulin sensitivity, ovulatory frequency, and menstrual regularity 1, 4, 6
• Even without weight loss, regular physical activity improves insulin sensitivity and lipid profiles 4

Pharmacologic Management

For Menstrual Irregularities and Endometrial Protection

Use combined oral contraceptive pills (COCs) as first-line pharmacologic therapy to regulate menstrual cycles, suppress ovarian androgen production, raise SHBG, reduce free testosterone, and prevent endometrial hyperplasia. 1, 4, 6

• COCs reduce the risk of endometrial cancer associated with chronic unopposed estrogen exposure from anovulation 4
• If COCs are contraindicated, use cyclic medroxyprogesterone acetate (10 mg daily for 10–14 days every 1–3 months) to provide endometrial protection 1

For Insulin Resistance and Metabolic Dysfunction

Add metformin (starting at 850 mg once daily, titrating to 850 mg three times daily or 1500–2000 mg daily as tolerated) to improve insulin sensitivity, glucose tolerance, lower circulating androgens, promote modest weight loss, and enhance menstrual regularity, especially in patients with pre-diabetic glycemic indices (HbA1c ≥5.5%). 1, 4, 3

• Metformin effects are more potent when combined with lifestyle interventions 7, 3
• Metformin is particularly beneficial in overweight and obese women but can be used in lean women with PCOS 3

For Hirsutism and Acne

Use COCs as first-line therapy for hirsutism and acne; if hirsutism persists after 3–6 months, add spironolactone (50–100 mg twice daily) as an anti-androgen. 1, 4, 3

• The combination of COC plus anti-androgen is the most effective medical regimen for reducing hirsutism 1, 3
• Mechanical hair removal (laser, electrolysis) can be used as adjuncts but should be combined with medical therapy to address underlying androgen excess 1, 3

For Infertility (When Pregnancy Desired)

Use letrozole (aromatase inhibitor) as first-line ovulation induction therapy for PCOS-related anovulatory infertility; clomiphene citrate is an alternative if letrozole is unavailable. 1, 6

• Lifestyle modification and weight loss (5–10%) should precede or accompany ovulation induction, as this significantly enhances ovulation rates 4, 2
• Metformin may be added to improve ovulation rates, particularly in obese women 4, 3
• Clomiphene citrate achieves an 80% ovulation rate and 50% conception rate 1

---

Long-Term Monitoring

• Repeat 2-hour oral glucose tolerance test every 1–2 years to detect progression to type 2 diabetes 4
• Measure fasting lipid panel annually to track cardiovascular risk 1, 4
• Monitor blood pressure and body weight every 6–12 months 1, 4
• Screen for anxiety, depression, body-image concerns, and eating disorders, which are highly prevalent in PCOS 1

---

Critical Pitfalls

• Do not diagnose PCOS in adolescents <2–3 years post-menarche, as menstrual irregularities and multifollicular ovaries are physiologic during this period 3
• Do not use ultrasound as a first-line diagnostic tool in adolescents due to high false-positive rates 1, 4, 3
• Do not use clomiphene citrate in functional hypothalamic amenorrhea, as it is ineffective; the presence of hyperandrogenism helps differentiate PCOS from FHA 4
• Do not rely on LH/FSH ratio >2 as a diagnostic criterion, as it is present in only 35–44% of women with PCOS 4, 2
• Recognize that up to 30% of women with confirmed PCOS have normal testosterone levels, so clinical hyperandrogenism plus oligomenorrhea alone can establish the diagnosis 4
• Understand that isolated polycystic ovarian morphology on ultrasound is found in 17–22% of asymptomatic women and should not alone establish a PCOS diagnosis 4